Ocumension files NDA in China for Nicox’s NCX 470 glaucoma therapy, marking a key regulatory milestone for the ophthalmic asset
Executive summary: Ocumension submitted an NDA to China’s NMPA for NCX 470, a glaucoma therapy co-developed with Nicox, on August 10, 2026. The filing represents a pivotal step toward commercializing NCX 470 in China, a major market for glaucoma treatments, and validates the therapeutic potential of Nicox’s nitric oxide-based platform.
Who is involved: Nicox (France), Ocumension (China), and China’s NMPA regulatory authority.
Likely next: NMPA review and potential approval within 12 months; if successful, Ocumension will initiate commercial launch in China under the partnership agreement.
Nicox announced that its partner Ocumension has submitted a New Drug Application (NDA) to China’s NMPA for NCX 470, a nitric oxide-donating bimatoprost eye drop designed to lower intraocular pressure in glaucoma patients. The filing follows positive Phase 3 results and positions the drug for potential approval in one of the world’s largest ophthalmic markets. This advancement reflects ongoing Sino-French collaboration in drug development and could accelerate commercialization timelines for NCX 470 in Asia.
Timeline
- — Nicox annonce la soumission d’une NDA pour NCX 470 en Chine par son partenaire Ocumension (GlobeNewswire)
- — Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension (GlobeNewswire)
- — Alebund's AP301 NDA Accepted for Review by China's NMPA (PR Newswire)
- — PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀ (GlobeNewswire)
Analysis — what this means
Likely next events
- NMPA acceptance review completion expected by Q4 2026
- Potential NMPA approval decision by Q3 2027
- Ocumension to announce China launch plan post-approval
- Nicox to report royalty milestones under partnership in 2027
Sectors affected
- Ophthalmic pharmaceuticals
- Glaucoma therapeutics
- China biopharma market
Regulatory implications
- NMPA review timeline: standard 12-month cycle for NDA submissions
- Post-approval requirements: Phase 4 commitment possible for long-term safety
- NDA submission enables eligibility for China’s priority review if clinical superiority is demonstrated
Historical parallels
- Alebund’s AP301 NDA acceptance by NMPA on August 7, 2026 (PR Newswire)
- PolyPid’s FDA NDA acceptance with priority review for D-PLEX on July 29, 2026 (GlobeNewswire)
- BridgeBio’s FDA NDA acceptance for Encaleret on July 22, 2026 (GlobeNewswire)
Key entities
Sources
Open the full interactive case file on Beyond →